Physician profile
Jay Timothy Ames
NPI 1538158134
$1,482.49
in general payments reported to CMS, 2019-2025
22 companies · $209 in 2025
The $209 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.04 · 2020: $217 · 2021: $196 · 2022: $564 · 2023: $92.03 · 2024: $151 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $452.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $349.83 | 2020-2025 | Mavyret |
| Janssen Pharmaceuticals, INC | $209.15 | 2021-2025 | Invega Sustenna, Spravato |
| Neurelis, INC. | $185.54 | 2022 | |
| Vanda Pharmaceuticals INC. | $143.43 | 2022-2024 | Fanapt |
| Glaxosmithkline, LLC. | $139.28 | 2019-2022 | |
| Owp Pharmaceuticals, INC. | $78.48 | 2024-2025 | Subvenite |
| Otsuka America Pharmaceutical, INC. | $72.65 | 2022-2024 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Lundbeck LLC | $43.22 | 2024 | Rexulti |
| Paratek Pharmaceuticals, INC. | $39.07 | 2024 | Nuzyra |
| Itamar Medical INC | $28.55 | 2023 | Watchpatone |
| E.R. Squibb & Sons, L.L.C. | $23.42 | 2025 | Cobenfy |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Gilead Sciences, INC. | $19.48 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.73 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.73 | 2025 | Trintellix |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $16.19 | 2025 | Aristada, Aristada Initio |
| Exact Sciences Corporation | $15.94 | 2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $14.39 | 2019 | |
| Lucid Diagnostics INC. | $12.96 | 2023 | |
| Genentech USA, INC. | $12.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $11.65 | 2019 | |
| Merck Sharp & Dohme LLC | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Ames listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.